FDA Biological Response Modifiers Advisory Committee
Executive Summary
Will discuss safety and efficacy of hematopoietic support regimens in the setting of myelotoxic chemotherapy May 25 & 26 at the Bethesda, Md. Ramada Hotel. On May 25, the meeting will begin at 10:30 a.m. The committee will reconvene at 8 a.m. May 26